World

Swiss health regulator approves first antimalarial for infants weighing 2-5kg

Jul 10, 2025

Geneva [Switzerland], July 10: Switzerland's health regulator Swissmedic has granted on Tuesday marketing authorization for Novartis Riamet Baby, also known as Coartem Baby, a novel antimalarial medicine specifically designed for infants weighing 2-5kg.
In a statement, Swissmedic said the authorization procedure involved close collaboration with national regulatory authorities from eight African countries. The World Health Organization (WHO) Global Malaria Program also participated in the scientific assessment. The next step is to ensure timely national access after the collaborative assessment.
Before the introduction of Coartem Baby, there was no approved malaria treatment for infants weighing less than 4.5 kg. As a result, these newborns were often treated with formulations intended for older children, which may increase the risk of overdose and toxicity, according to Novartis.
The new treatment, "ensuring even the smallest and most vulnerable can finally receive the care they deserve," is dissolvable, including in breast milk, and has a sweet cherry flavor to make it easier to administer.
According to the World Malaria Report 2024 published by the WHO, the WHO African Region accounted for about 94 percent of malaria cases and 95 percent of malaria deaths globally in 2023,with 76 percent of all deaths in this region among children under the age of five.
Source: Xinhua News Agency

More news

Hexaware and Abluva Join Forces to Deliver Secure Agentic AI Solutions for the Life Sciences Industry

Mumbai (Maharashtra) [India]/ Iselin (New Jersey) [US], July 10: Hexaware Technologies, a global provider of IT services and solutions, today announced a strategic partnership with Abluva, an innovator in agentic AI security, to address security challenges posed by autonomous AI agents in the Life Sciences industry. This collaboration brings together Hexaware's deep domain expertise and Abluva's groundbreaking Secure Intelligence Plane to help organizations in the sector deploy generative AI (GenAI) safely and in compliance with industry regulations. As Life Sciences organizations increasingly adopt agentic AI to enhance research, clinical trials, patient data management, and commercial operations, the partnership ensures that AI agents operate in a secure, governed, and auditable environment--without hindering innovation. Delivering Governed and Secure Generative AI Agents for Life Sciences Innovation.

Jul 10, 2025